Last reviewed · How we verify
Levofloxacin Ophthalmic
Levofloxacin ophthalmic is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, leading to bacterial cell death.
Levofloxacin ophthalmic is an antibiotic solution used to treat bacterial conjunctivitis. It is manufactured by the National University of Malaysia and does not have an FDA label. The drug works by inhibiting bacterial DNA gyrase, preventing bacterial replication. Common side effects include eye irritation, itching, and redness. It is generally well-tolerated but has specific contraindications and warnings for certain patient populations.
At a glance
| Generic name | Levofloxacin Ophthalmic |
|---|---|
| Also known as | Cravit 0.5%, Cravit(R), Cravit 1.5% |
| Sponsor | National University of Malaysia |
| Drug class | Fluoroquinolone |
| Target | DNA gyrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
It interferes with the bacterial DNA replication process by binding to and inhibiting the activity of DNA gyrase, an essential enzyme for bacterial DNA replication.
Approved indications
Common side effects
- Eye irritation
- Eye itching
- Eye redness
Key clinical trials
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis (PHASE2)
- Pilocarpine Use After Kahook Goniotomy (PHASE3)
- Assessment of the Effects and Tolerability of RD03/2016 for the Treatment of Bacterial Conjunctivitis in Adults (PHASE2)
- VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia (NA)
- A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery (PHASE1)
- Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery (PHASE4)
- Hyaluronic Acid-containing Artificial Tears in Post-cataract Surgery Dry Eye Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levofloxacin Ophthalmic CI brief — competitive landscape report
- Levofloxacin Ophthalmic updates RSS · CI watch RSS
- National University of Malaysia portfolio CI